Alvaro J. Alencar - Concepedia

Author

Alvaro J. Alencar

Sylvester Comprehensive Cancer Center ORCID

Also Known As

A. Alencar, A. J. Alencar, Alencar, A., Alvaro Alencar, Alvaro J Alencar, Alvaro J. Alencar, Alvaro Jose Alencar, Ana Helena Gonçalves de Alencar, Ana Valeria Silva Alencar

153

Publications

2.3K

Citations

H-Index

Concepts

All Affiliations

Sylvester Comprehensive Cancer Center University of Miami Sarah Cannon The University of Texas MD Anderson Cancer Center Memorial Sloan Kettering Cancer Center

About

Alvaro J. Alencar is an author at Sylvester Comprehensive Cancer Center specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	902
2	Immunology	6	6	703
3	Health Sciences	3	3	148
4	Engineering	1	1	129
5	Cell Biology	1	1	129

Alvaro J. Alencar

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study Anthony R. Mato, Nirav N. Shah, Wojciech Jurczak, The Lancet Phase 1/2Lymphoid NeoplasiaMedicineMalignant Blood DisorderImmunology	2021	432
Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment Ash A. Alizadeh, Andrew J. Gentles, Alvaro J. Alencar, Blood	2011	204
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia Anthony R. Mato, Jennifer A. Woyach, Jennifer R. Brown, New England Journal of Medicine	2023	190
MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP Alvaro J. Alencar, Raquel Malumbres, Goldi A. Kozloski, Clinical Cancer Research	2011	149
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127 Skye Montoya, Jessie Bourcier, Mark Noviski, Science EngineeringMixed-phenotype Acute LeukemiaGeneticsDisease Gene IdentificationMyeloid Neoplasia	2024	129
CD25 Expression Is Correlated with Histological Grade and Response to Denileukin Diftitox in Cutaneous T-Cell Lymphoma Rakhshandra Talpur, Daniel M. Jones, Alvaro J. Alencar, Journal of Investigative Dermatology Cutaneous T-cell LymphomaLymphoid NeoplasiaAutoimmune DiseaseHistological GradeImmunology	2006	104
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma Michael Wang, Wojciech Jurczak, Pier Luigi Zinzani, Journal of Clinical Oncology	2023	89
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial Matthew S. Davids, Danielle M. Brander, Haesook T. Kim, The Lancet Haematology Hematological MalignancyLymphoid NeoplasiaChronic Lymphocytic LeukaemiaMedicineYounger Patients	2019	70
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial Meletios Α. Dimopoulos, Paul G. Richardson, Nizar J. Bahlis, The Lancet Haematology Hematological MalignancyOncologyTransplantationHematologyClinical Trials	2022	44
Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study William G. Wierda, David Lewis, Paolo Ghia, Blood	2022	40

Page 1